搜索
Ligand Pharmaceuticals Inc
LGND添加自选
223.045USD
+1.635+0.74%
交易中 （美东）报价延迟15分钟
4.47B总市值
29.07市盈率 TTM
查看详细走势图
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+0.74%
5天
-1.93%
1月
+8.84%
6月
+6.57%
今年开始到现在
+17.97%
1年
+113.48%
TradingKey Ligand Pharmaceuticals Inc股票评分
单位: USD 更新时间: 2026-05-08操作建议
Ligand Pharmaceuticals Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名12/156位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价267.33。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Ligand Pharmaceuticals Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
Ligand Pharmaceuticals Inc亮点
亮点风险
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
业绩高增长
公司营业收入稳步增长，连续3年增长104.16%
利润高增长
公司净利润处于行业前列，最新年度总收入268.09M美元
业绩转盈
公司业绩转盈，最新年度盈利美元
估值合理
公司最新PE估值28.85，处于3年历史合理位
机构减仓
最新机构持股18.96M股，环比减少11.70%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值282.00
活跃度增加
近期活跃度增加，过去20天平均换手率1.11
分析师目标
根据
8
位分析师
买入
评级
268.778
目标均价
+21.39%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Ligand Pharmaceuticals Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Ligand Pharmaceuticals Inc简介
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
公司代码LGND
公司Ligand Pharmaceuticals Inc
CEODavis (Todd C)
网址https://www.ligand.com/
相关品种
